AstraZeneca drug backed
EU panel recommends approval for AstraZeneca's breast cancer treatment camizestrant, a potential competitor to Pfizer's Ibrance
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.